Not Medicare Enrolled
Dr. Douglas Heldreth, M.D.
Medical Oncology · Naples, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Heldreth from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Heldreth? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Heldreth
Dr. Douglas Heldreth is a medical oncology in Naples, FL, with 20 years in practice. Based on federal Medicare data, Dr. Heldreth performed 221,413 Medicare services across 4,760 unique beneficiaries.
Between the years covered by Open Payments, Dr. Heldreth received a total of $9,485 from 78 pharmaceutical and/or device companies across 493 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Heldreth is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 11% volume in FL$ $9,485 industry payments
Medicare Practice Summary
Medicare Utilization ↗221,413
Medicare services
Top 11% in FL for medical oncology
4,760
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,071 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 64,260 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 37,800 | $43 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 22,140 | $0 | $2 |
| Iron infusion (Injectafer) | 21,750 | $1 | $3 |
| Immune globulin infusion (Gammagard) | 11,820 | $36 | $108 |
| Denosumab injection (Prolia/Xgeva) | 10,800 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 10,660 | $1 | $5 |
| Daratumumab injection (Darzalex) | 9,180 | $38 | $110 |
| Paclitaxel chemotherapy injection | 7,879 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia | 4,180 | $6 | $23 |
| Dexamethasone injection (steroid) | 2,906 | $0 | $3 |
| Complete blood count (CBC) with differential | 2,519 | $8 | $29 |
| Blood draw (venipuncture) | 2,510 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,550 | $1 | $28 |
| Iron infusion (Monoferric) | 1,200 | $17 | $57 |
| Anti-nausea injection (ondansetron/Zofran) | 1,172 | $0 | $9 |
| Office visit, established patient (30-39 min) | 1,116 | $97 | $339 |
| Drug injection, under skin or into muscle | 1,011 | $11 | $69 |
| Injection, fulvestrant, 25 mg | 940 | $9 | $132 |
| Injection of additional new drug or substance into vein | 695 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 670 | $102 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 555 | $1 | $6 |
| Office visit, established patient (20-29 min) | 480 | $68 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 460 | $16 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 382 | $50 | $189 |
| Injection, carboplatin, 50 mg | 381 | $2 | $41 |
| Injection, diphenhydramine hcl, up to 50 mg | 308 | $1 | $3 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 298 | $3 | $205 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 257 | $23 | $84 |
| Administration of chemotherapy into vein, each additional hour | 180 | $22 | $79 |
| Injection of drug or substance into vein | 122 | $29 | $156 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 122 | $26 | $89 |
| Administration of additional new drug or substance into vein, 1 hour or less | 110 | $51 | $178 |
| Injection, zoledronic acid, 1 mg | 100 | $7 | $69 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 95 | $17 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 87 | $141 | $562 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 80 | $56 | $206 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 78 | $3 | $11 |
| Infusion into a vein for hydration, each additional hour | 76 | $10 | $42 |
| Infusion, normal saline solution , 1000 cc | 71 | $2 | $7 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 54 | $4 | $15 |
| New patient office visit (45-59 min) | 53 | $116 | $453 |
| Office visit, established patient (10-19 min) | 50 | $42 | $147 |
| Infusion into a vein for hydration, 31-60 minutes | 47 | $26 | $156 |
| Automated urinalysis | 38 | $2 | $8 |
| Red blood count, automated test | 35 | $4 | $10 |
| Office visit, established patient, complex (40-54 min) | 34 | $138 | $474 |
| Administration of additional new drug or substance into vein using push technique | 31 | $45 | $170 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 27 | $1 | $7 |
| Drawing of blood for a medical problem | 26 | $72 | $277 |
| New patient office visit (30-44 min) | 18 | $72 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
45.3% high complexity
51.4% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,485
Total received (2018-2024)
Avg $1,355/year across 7 years
Top 46% in FL for medical oncology
78
Companies
493
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,468 (99.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$17 (0.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,734
2023$1,657
2022$1,640
2021$666
2020$941
2019$1,048
2018$799
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$771
PFIZER INC.
$574
Myriad Genetic Laboratories, Inc.
$541
Janssen Biotech, Inc.
$488
Merck Sharp & Dohme LLC
$436
Celgene Corporation
$424
Novartis Pharmaceuticals Corporation
$412
Amgen Inc.
$392
Astellas Pharma US Inc
$370
AstraZeneca Pharmaceuticals LP
$327
Incyte Corporation
$292
Seagen Inc.
$283
GENZYME CORPORATION
$270
Gilead Sciences, Inc.
$237
Daiichi Sankyo Inc.
$206
Merck Sharp & Dohme Corporation
$187
Regeneron Healthcare Solutions, Inc.
$185
Genentech USA, Inc.
$182
BeiGene USA, Inc.
$179
Eisai Inc.
$169
GlaxoSmithKline, LLC.
$142
ARRAY BIOPHARMA INC
$128
Octapharma USA, Inc.
$119
Takeda Pharmaceuticals U.S.A., Inc.
$115
Lilly USA, LLC
$113
PharmaEssentia USA Corporation
$100
Bayer Healthcare Pharmaceuticals Inc.
$92
Boehringer Ingelheim Pharmaceuticals, Inc.
$90
ABBVIE INC.
$87
NanoString Technologies, Inc.
$85
Kite Pharma, Inc.
$75
Foundation Medicine, Inc.
$74
Bayer HealthCare Pharmaceuticals Inc.
$72
Alexion Pharmaceuticals, Inc.
$71
SERVIER PHARMACEUTICALS LLC
$66
Pharmacosmos Therapeutics Inc.
$60
Sobi, Inc
$59
Mirati Therapeutics, Inc.
$57
Jazz Pharmaceuticals Inc.
$53
Clovis Oncology, Inc.
$53
SOBI, INC
$52
Karyopharm Therapeutics Inc.
$52
Ipsen Biopharmaceuticals, Inc
$50
ADC Therapeutics America, Inc.
$48
PUMA BIOTECHNOLOGY, INC.
$46
Kyowa Kirin, Inc.
$44
MorphoSys, US Inc.
$39
Agios Pharmaceuticals, Inc.
$29
TESARO, Inc.
$27
Pharmacyclics LLC, An AbbVie Company
$25
Exelixis Inc.
$25
AbbVie, Inc.
$23
Tempus AI, Inc
$22
Deciphera Pharmaceuticals Inc.
$21
Immunomedics, Inc.
$20
Dendreon Pharmaceuticals LLC
$20
Taiho Oncology, Inc.
$20
Acrotech Biopharma Inc.
$20
Adaptive Biotechnologies Corporation
$19
ImmunoGen, Inc.
$19
Horizon Pharma plc
$18
AVEO Pharmaceuticals, Inc.
$18
GE HEALTHCARE
$17
Aurobindo Pharma USA, Inc.
$15
Sumitomo Pharma America, Inc.
$15
Partner Therapeutics, Inc.
$14
Array BioPharma Inc.
$14
AbbVie Inc.
$14
Sirtex Medical Inc
$13
JAZZ PHARMACEUTICALS INC.
$13
INSYS Therapeutics Inc
$12
Secura Bio, Inc.
$12
Acrotech Biopharma LLC
$12
Puma Biotechnology, Inc.
$12
Spectrum Pharmaceuticals Inc.
$12
Sysmex Inostics Inc
$10
Rigel Pharmaceuticals, Inc.
$5
Veracyte, Inc.
$0
Top 3 companies account for 19.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · Abraxane · Avastin · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Blincyto · Braftovi · CALQUENCE · CERDELGA · CEREZYME · COSELA · CYRAMZA · Cabometyx · Creon · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · EVENITY · Enhertu · Erleada · FARYDAK · FOTIVDA · FOUNDATIONONE · Fabhalta · Folotyn · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · INVOKAMET · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Leukine · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MYRISK · NERLYNX · NINLARO · NUWIQ · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSIGNA ASSAY · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SYNDROS · Stivarga · TASIGNA · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · Tibsovo · Trodelvy · ULTOMIRIS · VARUBI · VENCLEXTA · VERZENIO · VONJO · VONVENDI · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vyloy · WILATE · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XGEVA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zevalin · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $4 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
12
Per 100K population
3.1
County median income
$86,173
Nearest hospital
NAPLES COMMUNITY HOSPITAL
4.2 mi
4.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | — Not enrolled | N/A |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Heldreth is a mixed practice specialist, with above-average Medicare volume (top 11% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Heldreth experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Heldreth performed 64,260 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Heldreth receive payments from pharmaceutical companies?
Yes. Dr. Heldreth received a total of $9,485 from 78 companies across 493 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Heldreth's costs compare to other medical oncologys in Naples?
Dr. Heldreth's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Heldreth) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Naples
Browse medical oncologys in Naples ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology